Beyond the Endpoint

Danny Benjamin, principal investigator of the Pediatric Trials Network, joins Beyond the Endpoint to explain why kids are not small adults, especially when it comes to dosing. He shares how a neonatal intensive care unit conversation grew into a national network, how platform trials changed pediatric research, and what safeguards parents should look for. Learn more and view resources: https://dcri.org/blog/s3-ep-5-pediatric-dosing-protecting-children-through-research-not-it

Anuja Dokras, MD, MHCI, PhD, joins Emily O'Brien and new co-host Daniel Edmonston to explain why PCOS is now PMOS, polyendocrine metabolic ovarian syndrome. She traces the global effort behind the new name and how it could reduce stigma, improve frontline care, and open doors to new research funding. https://dcri.org/blog/s3-ep-4-whats-name-journey-pcos-pmos

Hosts Manesh Patel and Emily O'Brien look past the headlines on Novartis' Lp(a) drug trial results, AI agents in medicine, the FDA's Operation Trailblazer to speed up clinical trials, Dolly Parton's support for COVID research, and the case for steady NIH funding.

https://dcri.org/blog/s3-ep-3-beyond-headlines

Three former DCRI executive directors, Bob Harrington, Eric Peterson, and Lesley Curtis, join Beyond the Endpoint for part two of the institute's 30th anniversary series. They reflect on growth, crisis, inconvenient truths, and the culture they believe will carry DCRI through whatever comes next. https://dcri.org/blog/s3-ep-2-critical-filling-30-years-harrington-peterson-curtis

To mark DCRI's 30th anniversary, this first episode in a two-part series features founding director Robert Califf and current Executive Director Adrian Hernandez as they look back at the institute's evolution and ahead to its future. Part two arrives Sept. 23. https://dcri.org/blog/s3-ep-1-foundation-future-30-years-califf-hernandez

In this Beyond the Headlines episode, we examine the FDA's push for real-time clinical trial data, an executive order making psychedelic research a federal priority, advances in CAR T-cell therapy for autoimmune conditions, and viral claims about antihistamines as a treatment for premenstrual dysphoric disorder.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-16-beyond-headlines

COPD is the third leading cause of death worldwide. Yet the disease remains underdiagnosed and underfunded. Host Emily O'Brien and pulmonologist Chris Mosher discuss stigma, funding disparities, barriers to care, and promising research that's bringing new hope to patients.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-15-copd-gap-diagnosis-treatment-and-access

Why is it so hard to change our behavior, even when we know what we should be doing? Host Emily O'Brien sits down with urologist and DCRI faculty member Dr. Chuck Scales to discuss the science of behavior change and surprising findings from the PUSH trial, the largest kidney stone prevention trial to date.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-14-hard-habits-what-kidney-stones-teach-us-about-behavior-change

During a cardiac event, every minute without CPR reduces survival chances by 10%. In this episode, DCRI's Tyler Cope discusses a coordinated effort to train nearly 20,000 people across North Carolina in a single day and what it takes to get more bystanders to take action in an emergency.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-13-closing-gap-cardiac-arrest-survival-why-bystanders-matter

Nearly 40% of Americans have experienced back pain in the past three months, yet treatment hasn't kept pace with the science. Host Emily O'Brien talks with DCRI researcher Steven George about biopsychosocial models of care, pragmatic trials, and building a better system for chronic pain management.

🔗 Access resources related to this episode: https://dcri.org/blog/s2-ep-12-research-relief-raising-standard-back-pain-treatment